Gross Profit
United Therapeutics Gross Profit decreased by 5.6% to $648.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.7%, from $701.90M to $648.10M. Over 4 years (FY 2021 to FY 2025), Gross Profit shows an upward trend with a 15.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests improved manufacturing efficiency, favorable product mix, or higher pricing power, while a decrease may indicate rising raw material costs, supply chain inefficiencies, or competitive pricing pressure.
Detailed definition
Gross profit represents the residual earnings a company retains after deducting the direct costs associated with produci...
Peer comparison
Peers in the medical device and diagnostics sector typically maintain high gross margins due to intellectual property and specialized manufacturing, though these vary based on the specific product mix of nutritionals versus high-tech devices.
gross_profitHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $409.30M | $417.00M | $380.60M | $436.00M | $437.20M | $478.80M | $432.70M | $454.60M | $532.40M | $539.30M | $543.70M | $604.80M | $637.10M | $665.80M | $660.00M | $701.90M | $711.00M | $698.60M | $686.80M | $648.10M |
| QoQ Change | — | +1.9% | -8.7% | +14.6% | +0.3% | +9.5% | -9.6% | +5.1% | +17.1% | +1.3% | +0.8% | +11.2% | +5.3% | +4.5% | -0.9% | +6.3% | +1.3% | -1.7% | -1.7% | -5.6% |
| YoY Change | — | — | — | — | +6.8% | +14.8% | +13.7% | +4.3% | +21.8% | +12.6% | +25.7% | +33.0% | +19.7% | +23.5% | +21.4% | +16.1% | +11.6% | +4.9% | +4.1% | -7.7% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Tyvaso DPI | $220.70M | $235.50M | $234.80M | $254.40M | $266.70M | $280.90M | $279.90M | $247.10M |
| Orenitram | $101.20M | $105.60M | $102.10M | $112.40M | $117.20M | $124.30M | $114.30M | $128.20M |
| Nebulized Tyvaso | $131.50M | $149.80M | $135.30M | $155.30M | $148.80M | $135.10M | $119.30M | $118.60M |
| Remodulin | $134.50M | $115.00M | $121.10M | $124.40M | $120.40M | $112.80M | $119.90M | $110.50M |
| Unituxin | $47.90M | $56.30M | $65.30M | $53.00M | $55.60M | $44.30M | $56.40M | $48.60M |
| Adcirca | $3.10M | $3.90M | $2.90M | $3.40M | $3.80M | $5.30M | $4.40M | $1.90M |
| Total | $637.10M | $665.80M | $660.00M | $701.90M | $711.00M | $698.60M | $686.80M | $648.10M |
Tyvaso was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Gross Profit at Other Companies
Frequently Asked Questions
- What is United Therapeutics's gross profit?
- United Therapeutics (UTHR) reported gross profit of $648.10M in Q1 2026.
- How has United Therapeutics's gross profit changed year-over-year?
- United Therapeutics's gross profit decreased by 7.7% year-over-year, from $701.90M to $648.10M.
- What is the long-term trend for United Therapeutics's gross profit?
- Over 4 years (2021 to 2025), United Therapeutics's gross profit has grown at a 15.7% compound annual growth rate (CAGR), from $1.56B to $2.80B.
- What does gross profit mean?
- The total revenue earned from sales minus the direct costs required to manufacture and deliver those products.